English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

T he use of topical 5-aminolevulinic acid–photodynamic therapy (ALA-PDT) for the treatment ofBowendisease(squamouscell carcinomainsitu) is gaining acceptance. However, there is limited evidence for themostappropriate treatmentregimen,andclinical follow-up remains limited. The treatment of choice for Bowen disease is surgery. Five-year response rates have shown a recurrence rate of 19.0% after conventional surgery and 6.3% after Mohs micrographic surgery. In a comparison of ALA-PDT and cryotherapy, results significantly favored ALA-PDT. In a comparative study of ALA-PDT vs topical fluouracil, recurrence rates at 12 months were 7% and 27%, respectively. In a review of 11 PDT studies using broadly similar protocols, response rates of 90% to 100% were found after 1 to 3 treatment sessions, and an average recurrence rate of 12% was calculated. Importantly, however, follow-up periods varied widely (3-36 months), and therapy was often repeated. Our research group has investigated the role of light fractionation in the response of tissues to ALA-PDT in animal and clinical studies. In a randomized comparative study of the response of superficial basal cell carcinoma (sBCC) to ALA-PDT, our group showed a significantly higher complete response rate at 1 year (n=476) (P=.002) using a 2-fold illumination scheme (20 80 J/cm) with a 2-hour dark interval compared with a single illumination (75 J/cm).

Response of Bowen Disease to ALA-PDT Using a Single and a 2-Fold Illumination Scheme